Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

aTHermaVac - a Therapeutic Herpes Simplex Type 2 mRNA Vaccine

Reference number
Coordinator Eurocine Vaccines AB
Funding from Vinnova SEK 0
Project duration May 2024 - April 2026
Status Completed
Venture Swelife - Collaboration project for better health
Call Swelife - Collaborative projects for better health autumn 2023

Last updated 3 June 2024

Reference number 2023-03942